-+ 0.00%
-+ 0.00%
-+ 0.00%

Bausch + Lomb presents Phase 2 trial data for BL1107 glaucoma drug at ARVO 2026

PUBT·04/30/2026 11:03:07
Listen to the news
Bausch + Lomb presents Phase 2 trial data for BL1107 glaucoma drug at ARVO 2026
  • Bausch + Lomb flagged more than 40 scientific presentations for ARVO annual meeting in Denver, scheduled for May 3-7, 2026.
  • Data will be presented in the future, spanning commercial eye-care brands including Xiidra, Miebo, Vyzulta, Lumify, contact lenses, intraocular lenses, lens-care solutions.
  • Program includes clinical-trial readouts in glaucoma, featuring a Phase 2 study of BL1107 that evaluated intraocular pressure control and visual function.
  • Poster set also includes pain and retinal pipeline work, including BL1312 following photorefractive keratectomy plus BL1106 in a retinal degeneration model.
  • Company positioned the slate as evidence of broad portfolio momentum, with updates that could support product adoption in dry eye, glaucoma, cataract surgery, contact lenses.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Bausch + Lomb Corp. published the original content used to generate this news brief via Business Wire (Ref. ID: 20260430997236) on April 30, 2026, and is solely responsible for the information contained therein.